Consensus 8c. Cuts FY25 revenue view to $807M-$823M from $840M-$860M, consensus $846.39M. Cuts FY25 adjusted EBITDA view to $19M-$27M from $25M-$35M. Updated guidance reflects Q1 results and the current business outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics reports Q1 adjusted EPS (3c), consensus (5c)
- Myriad Genetics announces survey results on depression, anxiety
- MYGN Upcoming Earnings Report: What to Expect?
- Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study
- Myriad Genetics price target lowered to $9 from $11 at BofA